Merimepodib is an inosine monophosphate dehydrogenase (IMPDH) inhibitor with activity against hepatitis C virus (HCV). IMPDH catalyzes the rate-limiting step in the de novo synthesis of guanine nucleotides, and treatment with merimepodib reduces the intracellular guanine nucleotide levels that are required for RNA and DNA synthesis, resulting in antiproliferative and antiviral effect. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Merimepodibum and DTXSID70173639. Its PubChem CID is 153241.
Merimepodib
| CAS No | 198821-22-6 |
|---|---|
| Molecular Formula | C23H24N4O6 |
| Molecular Weight | 452.50 g/mol |
| Synonyms | [(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Merimepodib is an inosine monophosphate dehydrogenase (IMPDH) inhibitor with activity against hepatitis C virus (HCV).
The listed CAS number is 198821-22-6.
The listed molecular formula is C23H24N4O6.
The listed molecular weight is 452.50 g/mol.
[(3S)-oxolan-3-yl] N-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate.
The source lists Merimepodibum and DTXSID70173639.